Search

Find exactly what you’re looking for.
Search

Service
Showing 1-20 of 25 results

Congratulations! After spending months preparing and submitting your marijuana license application, you have been selected by the Delaware Office of Marijuana Commissioner (OMC) to receive a coveted adult-use marijuana license — now the real work starts. Over the last eight years, I have helped...

Introduction In May 2022, a jury in the Circuit Court for Fairfax County, Virginia awarded Appian Corp. (Appian) in excess of $2 billion in damages from Pegasystems, Inc. (Pegasystems) for misappropriating Appian’s trade secrets in violation of the Virginia Uniform Trade Secrets Act (VUTSA). This...

Saul Ewing LLP is proud to announce that Charles M. Lizza, Vice Chair of the firm’s Litigation Department, was named to the NJBIZ 2024 Law Power 50 list. This is the sixth year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list...

NEW YORK, (JULY 15, 2024) – Saul Ewing LLP is expanding its Litigation Practice with two attorneys, Partners James Chou and Peter Zlotnick, who together bring more than 55 years of legal experience to their work representing clients in a variety of complex litigation. They are resident in the firm’s...

Introduction On June 18, 2024, the Federal Trade Commission (“FTC”) unanimously agreed to submit a comment supporting a recent proposed U.S. Patent and Trademark Office (“PTO”) rule that would mandate the disclosure of all settlement agreements made between parties appearing before the Patent Trial...

On June 27, 2024, the Supreme Court released its highly anticipated opinion in Harrington v. Purdue Pharma L.P., Case No. 23-124. The question before the Court was whether the bankruptcy code authorizes a court to approve, as part of a chapter 11 plan, a release that extinguishes claims held by...

Delene Lantz, Counsel, Saul Ewing LLP, will speak at the PA Township Association of Supervisor’s (PSATS) Secretary and Township Managers Summit in Boalsburg, PA on Tuesday, June 18th. Her topic will be Managing Right-to-Know Requests. Get caught up on the latest news, RTKL decisions, and best...

In a conversational 30-minute forum over Zoom, Saul Ewing attorneys hosted a discussion on emerging industry developments and common issues that cannabis businesses face today. This month's program featured content covering current regulatory landscape and how it impacts your business. Interested in...

Candice L. Kline, Partner at Saul Ewing, will be speaking in an upcoming live video webinar, " Intersection of Bankruptcy and ADR: Issues for Creditors, Counterparties, and Plan Proponents " scheduled for Friday, February 16, 1:00pm-2:30pm EST. Alternative dispute resolution (ADR) issues arise in...

Saul Ewing attorneys hosted a timely discussion on topics relating to Minnesota’s new adult-use cannabis law. During this one-hour program, we examined the implications of the law for all Minnesota employers, including those relating to drug testing and drug-free workplace policies. We also...

January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...

Financial Poise Webinars™ announces “Focus on Manufacturing,” a live webinar premiering November 9th at 2:00 PM CST. This webinar is co-produced by West LegalEdCenter™ and part of the “ Chapter 11- Industry Focus 2023 ” series. It will feature Jonathan Friedland (Much Shelist, P.C.); Ken Yager...

On November 1, 2023, Candice Kline will speak during the Financial Poise Webinar RESTRUCTURING, INSOLVENCY & TROUBLED COMPANIES 2023. The topic which she will speak on is "Bad Debtor Owes Me Money."

Contingent Liability Insurance Demystified Partner Brian Michalek will speak on a panel during the 2023 Transaction Solutions Symposium. More information to come.

​On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...

For More Information
Contact us